TET2 and acute myeloid leukemia: Evidence showed that the patients with TET2 mutations had worse overall survival compared with the patients with wild-type TET2 in 93 patients with AML.38 However, other studies showed no survival association in 111 patients with de novo AML106 and in a cohort of 247 patients with secondary AML.107 Therefore, the significance of TET2 mutations in AML prognosis remains to be elucidated.